COMP <GO>
ARDX vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Ardelyx Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ARDX 2
— ABBV 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ABBV
LAST: $3.10 (0.00%) • MKT CAP: $772.5M
balance-sheet
0.20
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARDX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARDX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.30% | 70.20% | +20.10 | ARDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.70% | 29.00% | -61.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.69% | 3.47% | -9.16 | ABBV | /fcf-yield <GO> |
| Operating Margin | -10.10% | 24.60% | -34.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -15.20% | 6.90% | -22.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 22.10% | 8.60% | +13.50 | ARDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.3 | 65.1 | -27.81 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $772.5M | $513.86B | -$513.09B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARDX REV | ABBV REV | ARDX GROSS % | ABBV GROSS % | ARDX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $407.3M | $61.16B | 90.3% | 70.2% | -$44.0M | $17.82B |
| FY 2024 | $333.6M | $56.33B | 84.8% | 70.0% | -$45.8M | $17.83B |
| FY 2023 | $124.5M | $54.32B | — | — | -$89.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARDX // BETA —
ABBV // BETA 1.15